Sclerostin in mineralized matrices and van Buchem disease

Authors
  • L. van der Wee-Pals
  • W. Balemans
  • H.J. Oostenbroek
  • W. Van Hul
  • H. Hamersma
  • F.G. Dikkers
  • N.A.T. Hamdy
  • S.E. Papapoulos
  • C.W.G.M. Löwik
Publication date 2009
Journal Journal of Dental Research
Volume | Issue number 88 | 6
Pages (from-to) 569-574
Organisations
  • Faculty of Dentistry (ACTA)
Abstract
Sclerostin is an inhibitor of bone formation expressed by osteocytes. We hypothesized that sclerostin is expressed by cells of the same origin and also embedded within mineralized matrices. In this study, we analyzed (a) sclerostin expression using immunohistochemistry, (b) whether the genomic defect in individuals with van Buchem disease (VBD) was associated with the absence of sclerostin expression, and (c) whether this was associated with hypercementosis. Sclerostin was expressed by cementocytes in mouse and human teeth and by mineralized hypertrophic chondrocytes in the human growth plate. In individuals with VBD, sclerostin expression was absent or strongly decreased in osteocytes and cementocytes. This was associated with increased bone formation, but no overt changes in cementum thickness. In conclusion, sclerostin is expressed by all 3 terminally differentiated cell types embedded within mineralized matrices: osteocytes, cementocytes, and hypertrophic chondrocytes.
Document type Article
Published at https://doi.org/10.1177/0022034509338340
Permalink to this page
Back